Celgene Co. (NASDAQ:CELG) – Investment analysts at Leerink Swann raised their FY2021 earnings per share (EPS) estimates for shares of Celgene in a research note issued on Wednesday. Leerink Swann analyst G. Porges now forecasts that the biopharmaceutical company will earn $15.22 per share for the year, up from their prior forecast of $15.18. Leerink Swann has a “Outperform” rating on the stock.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.21. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. Celgene had a return on equity of 53.00% and a net margin of 31.79%. Celgene’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 earnings per share. COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/07/fy2021-eps-estimates-for-celgene-co-increased-by-leerink-swann-nasdaqcelg.html.

Several other equities research analysts also recently commented on CELG. Zacks Investment Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, March 9th. Cann reiterated a “buy” rating and issued a $148.00 target price on shares of Celgene in a research report on Tuesday, April 4th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $148.00 target price on shares of Celgene in a research report on Wednesday, April 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $154.00 target price on shares of Celgene in a research report on Tuesday, April 11th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $162.00 target price on shares of Celgene in a research report on Wednesday, April 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Celgene presently has an average rating of “Buy” and a consensus target price of $139.80.

Celgene (CELG) traded up 0.74% on Friday, reaching $132.93. The company had a trading volume of 1,408,488 shares. The stock has a market capitalization of $103.79 billion, a P/E ratio of 49.92 and a beta of 1.89. Celgene has a 12-month low of $96.93 and a 12-month high of $135.18. The stock’s 50-day moving average price is $121.46 and its 200-day moving average price is $120.59.

In other Celgene news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James J. Loughlin sold 9,250 shares of the firm’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the completion of the sale, the director now owns 32,169 shares in the company, valued at $3,988,956. The disclosure for this sale can be found here. Insiders sold a total of 237,005 shares of company stock worth $31,515,142 over the last 90 days. Company insiders own 0.95% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CELG. Motco increased its position in Celgene by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene during the first quarter worth approximately $118,000. Carroll Financial Associates Inc. increased its position in Celgene by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the last quarter. Oakworth Capital Inc. increased its position in Celgene by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in Celgene during the fourth quarter worth approximately $146,000. 78.26% of the stock is owned by institutional investors.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.